

28.05.2018

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code : 524742

By BSE Listing

National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code : CAPLIPOINT.

By NEAPS

Dear Sirs,

**SUB: AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2018
AND RECOMMENDATION OF DIVIDEND FOR THE YEAR ENDED MARCH 31, 2018.**

The Board of Directors of the Company at their meeting held today:

1. Approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31,2018
2. Recommended a dividend of Rs. 2 (Rupees Two) (100 %) per equity share of Rs.2/- each for the financial year ended March 31, 2018.

Pursuant to Regulation 30 and 33 of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, we herewith enclose:

1. Audited Financial Results (Standalone and Consolidated) for quarter and year ended March 31, 2018.
2. Audit Report (Standalone and Consolidated)for the above Audited Financial Results
3. Press release on the Audited Financial Results.

Pursuant to Regulation 33 (3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare and confirm that the Auditors Report (Standalone and Consolidated) on the Audited Financial Results for quarter and year ended March 31,2018 contains unmodified opinion only.

The Board of Directors meeting commenced at 11.30 AM and concluded at 2.55 PM.

Kindly take the same on your records.

Thanking You,

Yours Faithfully,
For Caplin point Laboratories Limited



Company Secretary
Enclosure : As Above

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

AUDITED (STANDALONE) FINANCIAL RESULTS FOR THE THREE MONTHS AND YEAR ENDED 31st MARCH 2018

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

Particulars	Three Months Ended			Financial Year Ended	Financial Year Ended
	31.03.2018 (1)	31.12.2017 (2)	31.03.2017 (3)	31.03.2018 (4)	31.03.2017 (5)
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
INR In Lakhs					
Income:					
I Revenue from operations	11,044.13	11,083.42	9,434.67	42,657.39	34,154.93
II Other income Including dividend/share of profit from subsidiary/LLP	306.83	224.56	379.84	2,331.33	1,251.25
III Total Income (I+II)	11,350.96	11,307.98	9,814.51	44,988.72	35,406.18
Expenses:					
a. Cost of materials consumed	2,079.47	2511.68	1,688.82	9,021.63	6,447.19
b. Purchase of traded goods	2,642.13	2174.19	2,274.67	9,228.22	9,769.77
c. Changes in inventories of finished goods, stock in trade and work in progress	(266.80)	166.74	164.22	(238.77)	(23.26)
d. Employee benefit expenses	981.71	986.76	802.86	3,882.04	3,058.47
e. Finance cost	1.36	1.46	3.47	6.12	12.75
f. Depreciation & Amortisation Expenses	617.41	452.47	503.05	1,898.78	1,325.99
g. Exchange Fluctuation Loss	-	-	-	-	-
h. Other Expenses	2124.50	1546.48	1,375.71	6,585.40	5,557.44
i. Total Expenses	8,179.78	7,839.78	6,812.80	30,383.42	26,148.35
V Profit before exceptional items and Tax (IV-V)	3,171.18	3,468.20	3,001.71	14,605.30	9,257.83
VI Exceptional items	-	-	-	-	-
VII Profit Before Tax (VI-VII)	3,171.18	3,468.20	3,001.71	14,605.30	9,257.83
VIII Tax Expenses					
(1) Current Tax	1,014.31	924.53	608.44	4,054.79	1,937.43
(2) MAT Credit	-	-	(434.95)	-	(434.95)
(3) Deferred Tax	(0.94)	185.12	644.97	319.42	723.65
Total Tax Expenses	1,013.37	1,109.65	818.46	4,374.21	2,226.13
IX Net Profit for the period (VIII-IX)	2,157.81	2,358.55	2,183.25	10,231.09	7,031.70
X Other Comprehensive Income - Net of Income Tax	64.23	4.05	3.76	76.60	16.16
XI Total Comprehensive Income For The Period (X+XI)	2,222.04	2,362.60	2,187.01	10,307.69	7,047.86
XII Paid up Equity Share Capital (Face value of the share - Rs 10/- each has been sub-divided into 5 equity shares of Rs 2/- each wef 20 Oct 2016)	1,512.07	1,511.53	1,511.53	1,512.07	1,511.53
XIII Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year					18,479.76
XIV Earnings/(Loss) Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share (post sub division of shares)					
(a) Basic (in Rupees)	2.94	3.13	2.89	13.64	9.30
(b) Diluted (in Rupees)	2.93	3.11	2.89	13.57	9.30



Handwritten signature in blue ink.

Notes :

1) The Company adopted Indian Accounting Standards ("Ind AS") from 1st April 2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting pronouncement generally accepted in India. Financial results of all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.

2) Reconciliation between financial results as previously reported under Previous GAAP and Ind AS presented are as under:

a. Profit Reconciliation

Particulars	INR in Lakhs	
	Three months ended 31.03.2017	Year ended 31 .03.2017
Net profit under previous I GAAP	2,189.87	7086.32
Income on account of fair Value Adjustment of Rental Deposit	0.39	1.56
Amortisation of Rental Deposit	(0.41)	(1.64)
Fair Value measurement of Mutual fund	10.49	10.49
Actuarial (gain) / Loss on employee defined benefit funds recognized in Other Comprehensive Income	(3.76)	(16.16)
Impact on rent straight lining	0.67	2.68
Other fair value measurement impact	(18.57)	(80.44)
Deferred Tax	4.57	28.89
Net Profit as per Ind AS	2,183.25	7,031.70
Other Comprehensive Income - Net of Income Tax	3.76	16.16
Total Comprehensive Income For The Period	2,187.01	7,047.86

b. Equity Reconciliation

Particulars	INR in Lakhs	
	As on 31.03.2017	
Equity as per I GAAP	19,955.00	
Fair Valuation/ Amortised cost of financial assets / liabilities	46.93	
Tax impact on above adjustment	(10.64)	
Equity as per Ind AS	19,991.29	

- 3) The figures for the quarter ended 31 March 2018 are balancing figures between the audited figures in respect of the full financial year and the year-to-date figures upto the third quarter of the Financial Year.
- 4) Results for the quarter and year ended 31 March 2018 periods presented have been audited by the statutory auditors of the Company. An unqualified opinion has been issued by them thereon.
- 5) The financial results of the company have been reviewed by the Audit Committee of the Board and have been approved by the Board of Directors of the Company at their meeting held on 28th May 2018.
- 6) The Board of Directors at their meeting held on 28th May 2018, have recommended a final dividend of 100%, i.e Rs 2.00 per equity share of Rs 2/ each.
- 7) The Other income for the Financial Year ('FY') 2018 includes a dividend income of Rs 1139.50 lakhs from 100% foreign subsidiary in Hong Kong, as compared to NIL during the FY ended 31 March 2017. The provision for current tax includes the tax liability under the provisions of Income Tax Act, 1961 on such dividend income.
- 8) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 9) During the three months period ended 31st March 2018, the Company had allotted 26,750 equity shares of Rs 2/- each under the Employee Stock Option Scheme 2015 and the total number of equity shares of the Company stands at 7,56,03,500 as on 31st March 2018.
- 10) Prior year / period figures are regrouped / rearranged in accordance with Ind AS.



For **CNGSN & ASSOCIATES LLP**
CHARTERED ACCOUNTANTS
 F R No: 0049155 S200036
K. Parthasarathy
K. PARTHASARATHY
 PARTNER
 MEMB.No. 018394

Sridhar Ganesan

Dr Sridhar Ganesan
 Managing Director

Place : Chennai
 Date 28th May 2018

Standalone Statement of Assets & Liabilities as at March 31, 2018

INR in Lakhs

Particulars	Audited	
	As at 31.03.2018	As at 31.03.2017
ASSETS		
(1) Non-Current Assets		
(a) Property, Plant and Equipment	16,740.16	15,044.76
(b) Capital work-in-progress	1,529.12	341.52
(c) Other Intangible assets	191.74	130.30
(d) Financial Assets		
(i) Investments	4,298.83	1,457.71
(ii) Loans	1,110.91	1,059.41
Sub-total-Non current assets	23,870.76	18,033.70
(2) Current Assets		
(a) Inventories	2,845.56	2,229.49
(b) Financial Assets		
(i) Investments	522.26	420.00
(ii) Trade Receivables	8,635.31	320.56
(iii) Cash and Cash equivalents	1,139.31	2,695.74
(iv) Bank balances other than (iii) above	1,689.15	4,970.05
(v) Loans	2,346.87	2,773.95
(c) Other Current Assets	31.02	263.02
Sub-total-Current assets	17,209.47	13,672.81
Total	41,080.23	31,706.51
Equity and Liabilities		
(1) Equity		
Equity Share capital	1,512.07	1,511.53
Other Equity	28,048.36	18,479.76
Sub-total-Total Equity	29,560.43	19,991.29
(2) Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	32.19	47.51
(ii) Other financial liabilities	-	5.39
(b) Deferred Tax Liabilities (Net)	2,216.07	1,896.64
(c) Other Long term liabilities	537.61	
(d) Provisions	-	40.00
Sub-total-Non current liabilities	2,785.87	1,989.54
(3) Current Liabilities		
(a) Financial Liabilities		
(i) Trade Payables	7,289.50	6,600.54
(b) Other Current Liabilities	1,266.07	2,937.43
(c) Provisions	178.36	187.70
Sub-total-Current liabilities	8,733.93	9,725.67
Total	41,080.23	31,706.51



Luha

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN: L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

AUDITED (CONSOLIDATED) FINANCIAL RESULTS FOR THE THREE MONTHS AND YEAR ENDED 31st MARCH 2018

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

	Particulars	Three Months ended			Financial Year	Financial Year
		31.03. 2018	31.12. 2017	31.03.2017	Ended	Ended
		(1)	(2)	(3)	(4)	(5)
		(Unaudited)	(Audited)	(Audited)	(Audited)	
INR in lakhs						
	Income:					
I	Revenue from operations	14341.08	14,160.80	11,805.71	53,984.20	40,164.85
II	Other income	289.86	232.76	438.13	1,266.52	995.53
III	Total Income (I+II)	14630.94	14,393.56	12,243.84	55,250.72	41,160.38
IV	Expenses:					
	a. Cost of materials consumed	2,079.47	2,511.68	1,689.33	9,021.63	6,477.70
	b. Purchase of traded goods	4,406.01	3,859.29	3,103.99	15,035.10	11,941.57
	c. Changes in inventories of finished goods, stock in trade and work in progress	(266.80)	166.74	263.82	(238.77)	73.62
	d. Employee benefit expenses	1,013.94	986.76	819.31	3,914.27	3,084.59
	e. Finance cost	1.36	1.46	2.12	6.12	12.75
	f. Depreciation & Amortisation Expenses	617.57	452.47	499.10	1,899.50	1,329.84
	g. Exchange Fluctuation Loss	-	-	-	-	-
	h. Other Expenses	2,236.57	1,557.48	1,607.01	6,775.04	6,145.61
	i. Total Expenses	10,088.12	9,535.88	7,984.68	36,412.89	29,065.68
V	Profit before exceptional items and Tax (III-IV)	4,542.82	4,857.68	4,259.16	18,837.83	12,094.70
VI	Exceptional items	-	-	-	-	-
VII	Profit Before Tax (V-VI)	4,542.82	4,857.68	4,259.16	18,837.83	12,094.70
VIII	Tax Expenses					
	(1) Current Tax	1,014.43	924.53	716.71	4,054.91	2,255.70
	(2) MAT credit	-	-	(434.94)	-	(434.94)
	(3) Deferred Tax	(0.94)	185.12	644.97	319.42	723.65
	Total Tax Expenses	1,013.49	1,109.65	926.74	4,374.33	2,544.41
IX	Net Profit for the period (VI - VIII)	3,529.33	3,748.03	3,332.42	14,463.50	9,550.29
X	Other Comprehensive Income - Net of Income Tax	64.23	4.05	3.76	76.60	16.16
XI	Total Comprehensive Income For The Period (IX - X)	3,593.56	3,752.08	3,336.18	14,540.10	9,566.45
XII	Profit attributable to:					
	Owners of the Company	3,535.78	3,752.49	3,340.33	14,478.77	9,561.24
	Non- controlling interests	(6.45)	(4.46)	(7.91)	(15.27)	(10.95)
		3,529.33	3,748.03	3,332.42	14,463.50	9,550.29
XIII	Total Comprehensive Income For The Period attributable to					
	Owners of the Company	3,600.01	3,756.54	3,344.09	14,555.37	9,577.40
	Non- controlling interests	(6.45)	(4.46)	(7.91)	(15.27)	(10.95)
		3,593.56	3,752.08	3,336.18	14,540.10	9,566.45
XIV	Paid up Equity Share Capital (Face value of the share - Rs 10/- each has been sub-divided into 5 equity shares of Rs 2/- each wef 20 Oct 2016)	1,512.07	1,511.53	1,511.53	1,512.07	1,511.53
XV	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year					20,944.46
XVI	Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share (post sub division of shares)					
	(a) Basic (in Rupees)	4.76	4.96	4.41	19.26	12.65
	(b) Diluted (in Rupees)	4.74	4.94	4.41	19.16	12.65



Signature

Notes:

- 1) The Company adopted Indian Accounting Standards ("Ind AS") from 1st April 2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting pronouncement generally accepted in India. Financial results of all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.
- 2) Reconciliation between financial results as previously reported under Previous GAAP and Ind AS presented are as under:
 - a. Profit Reconciliation

INR in Lakhs

Particulars	INR in Lakhs	
	Three months ended 31.03.2017	Year ended 31.03. 2017
Net profit under previous I GAAP	3,329.84	9,604.90
Income on account of fair Value Adjustment of Rental Deposit	0.39	1.56
Amortisation of Rental Deposit	(0.41)	(1.64)
Fair Value measurement of Mutual fund	10.49	10.49
Actuarial (gain) / Loss on employee defined benefit funds recognized in Other Comprehensive Income	(3.76)	(16.16)
Impact on rent straight lining	0.67	2.68
Other fair value measurement impact	(18.57)	(80.43)
Deferred Tax	13.77	28.89
Net Profit as per Ind AS	3,332.42	9,550.29
Other Comprehensive Income - Net of Income Tax	3.76	16.16
Total Comprehensive Income For The Period	3,336.18	9,566.45
Less: Non Controlling Interest	(7.91)	(10.95)
Total Comprehensive Income attributable to owners	3,344.09	9,577.40

b. Equity Reconciliation

INR in Lakhs

Particulars	INR in Lakhs	
	As on 31.03.2017	
Equity as per I GAAP	22,419.70	
Fair Valuation/ Amortised cost of financial assets / liabilities	46.93	
Tax impact on above adjustment	(10.64)	
Equity as per Ind AS	22,455.99	

- 3) The figures for the quarter ended 31 March 2018 are balancing figures between the audited figures in respect of the full financial year and the year-to-date figures upto the third quarter of the Financial Year.
- 4) Results for the quarter and year ended 31 March 2018 periods presented have been audited by the statutory auditors of the Company. An unqualified opinion has been issued by them thereon.
- 5) The financial results of the company have been reviewed by the Audit Committee of the Board and have been approved by the Board of Directors of the Company at their meeting held on 28th May 2018.
- 6) The Board of Directors at their meeting held on 28th May 2018, have recommended a final dividend of 100%, i.e Rs 2.00 per equity share of Rs 2/ each.
- 7) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 8) During the three months period ended 31st March 2018, the Company had allotted 26,750 equity shares of Rs 2/- each under the Employee Stock Option Scheme 2015 and the total number of equity shares of the Company stands at 7,56,03,500 as on 31st March 2018.
- 9) Provision for current tax for the Financial Year ('FY') includes the tax liability under the provisions of Income Tax Act, 1961 on the dividend distributed by 100% foreign subsidiary in Hong Kong.
- 10) Prior year / period figures are regrouped / rearranged wherever necessary.



Dr Sridhar Ganesan
Managing Director

Place : Chennai

Date : 28th May 2018



For CNGSN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
F R No: 0049155 / S200036



K. PARTHASARATHY
PARTNER
MEMB.No. 018394

Consolidated Statement of Assets & Liabilities as at March 31, 2018

INR in Lakhs

Particulars	Audited	Audited
	As at 31.03.2018	As at 31.03.2017
ASSETS		
(1) Non-Current Assets		
(a) Property, Plant and Equipment	16,741.82	15,046.06
(b) Capital work-in-progress	1,529.12	341.52
(c) Other Intangible assets	206.51	137.22
(d) Financial Assets		
(i) Investments	4,144.88	1,324.39
(ii) Loans	1,123.20	1,066.81
Sub-total-Non current assets	23,745.52	17,916.00
(2) Current Assets		
(a) Inventories	2,845.56	2,229.49
(b) Financial Assets		
(i) Investments	522.26	420.00
(ii) Trade Receivables	12,588.15	3,302.48
(iii) Cash and Cash equivalents	6,237.66	4,336.92
(iv) Bank balances other than (iii) above	1,690.20	4,970.56
(v) Loans	2,384.61	2,399.72
(c) Other Current Assets	31.06	263.02
Sub-total-Current assets	26,299.50	17,922.20
Total	50,045.02	35,838.20
Equity and Liabilities		
(1) Equity		
Equity Share capital	1,512.07	1,511.53
Other Equity	34,871.08	20,944.46
Equity attributable to shareholders of the company	36,383.15	22,455.99
Non controlling interest	9.04	36.22
Sub-total-Total Equity	36,392.19	22,492.21
(2) Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	32.19	47.51
(ii) Other financial liabilities	-	5.39
(b) Deferred Tax Liabilities (Net)	2,216.07	1,896.64
(c) Other Long term liabilities	537.61	-
(d) Provisions	-	40.00
Sub-total-Non current liabilities	2,785.87	1,989.54
(3) Current Liabilities		
(a) Financial Liabilities		
(i) Trade Payables	9,422.53	7,860.04
(b) Other Current Liabilities	1,266.07	3,308.71
(c) Provisions	178.36	187.69
Sub-total-Current liabilities	10,866.96	11,356.45
Total	50,045.02	35,838.20



Handwritten signature



CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No. 43, (Old No. 22)
Vijayaraghava Road, T. Nagar, Chennai - 600 017.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

S. NEELAKANTAN
B.Com., FCA

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

CHINNSAMY GANESAN
B.Com., FCA, DISA (ICAI)

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

K. PARTHASARATHY
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., FCA

INDEPENDENT AUDITOR'S REPORT ON STANDALONE FINANCIAL RESULTS OF CAPLIN POINT LABORATORIES LIMITED, CHENNAI FOR QUARTER ENDED MARCH 31 2018 AND YEAR ENDED MARCH 31, 2018.

To
Board of Directors of
CAPLIN POINT LABORATORIES LIMITED, CHENNAI

1. We have audited the accompanying statements of Standalone financial results of **Caplin Point Laboratories Limited** ("the company") for the quarter ended March 31, 2018 and Financial Year ended March 31, 2018, ("the statements") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July. This statement is the responsibility of the Company Management and approved by the Board of Directors, has been prepared on the basis of the related standalone Financial Statements which are in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the statement based on our audit of such financial statements.
2. We conducted our audit in accordance with the auditing standards issued by the Institute of Chartered Accounts of India. Those standards require that we comply with the ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s).

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the results included in the statements. The procedures selected depend on the auditor's judgment, including the risk of material misstatement of the Results included in the statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Results included in the Statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting principles used and the reasonableness of the significant estimates made by management, as well as evaluating the overall presentation of the statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



3. In our opinion and to the best of our information and according to the explanations given to us the statements:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016; and
- ii. gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, of the net profit and Total comprehensive income and other financial information of the Company for the quarter ended 31/03/2018 as well for the Financial Year ended March, 2018.

For CNGSN & ASSOCIATES LLP

Chartered Accountants

Firm Registration No. 004915S /S200036


K. Parthasarathy

Partner

(Membership No. 018394)



Place: Chennai

Date: 28/05/2018



CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No. 43, (Old No. 22)
Vijayaraghava Road, T. Nagar, Chennai - 600 017.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

CHINNSAMY GANESAN
B.Com., FCA, DISA (ICAI)

S. NEELAKANTAN
B.Com., FCA

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

R. THIRUMALMARUGAN
M.Com., FCA

K. PARTHASARATHY
B.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

V. VIVEK ANAND
B.Com., FCA

E.K. SRIVATSAN
B.Com., FCA

AUDITOR'S REPORT ON THE CONSOLIDATED FINANCIAL RESULTS OF CAPLIN POINT LABORATORIES LIMITED, CHENNAI FOR QUARTER ENDED MARCH 31 2018 AND FINANCIAL YEAR ENDED MARCH 31, 2018.

To
Board of Directors of
CAPLIN POINT LABORATORIES LIMITED

1. We have audited the accompanying statements of Consolidated Financial Results of Caplin Point Laboratories Limited "the Holding Company" and its subsidiaries for the quarter and Financial Year ended March 31, 2018 ("the statement") being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement which is the responsibility of the Holding company's management and approval by the Board of Directors, has been prepared on the basis of the related Consolidated Financial Statements which are in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the statement, based on the audit of such financial statements.
2. We conducted our audit in accordance with the auditing standards issued by the Institute of Chartered Accounts of India. Those standards require that we comply with the ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s).


An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the results included in the statements. The procedure selected depend on the auditor's judgment, including the risk of material misstatement of the Results included in the statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Results included in the Statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting principles used and the reasonableness of the significant estimates made by management, as well as evaluating the overall presentation of the statement.



We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

3. We did not audit the financial statements of two of the subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of Rs 8964.77 Lakhs as at 31st March 2018, total revenues of Rs 10261.99 Lakhs, total net profit after tax Rs 4247.68 Lakhs for the year ended on that date, as considered in the consolidated financial results. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion, on the statements, insofar as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors.
4. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the report of the other auditors referred to in paragraph 3 above, the statement:
 - i. includes the results of entities as given below:
 - a. Argus Salud Pharma LLP
 - b. Caplin Point Far East Limited
 - c. Caplin Point Laboratories Colombia SAS
 - ii. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016; and
 - iii. gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated Profit, total comprehensive income and other financial information for the quarter and the Financial Year ended March 31, 2018.
5. The comparative financial information for the year ended 31st March, 2018 in respect of the above-mentioned subsidiaries included in this Consolidated Results included in the Statement, prepared in accordance with the Ind AS have been audited by other auditors and have been relied upon by us.

For CNGSN & ASSOCIATES LLP
Chartered Accountants
Firm Registration No. 004915S /S200036


K. Parthasarathy
Partner
(Membership No. 018394)



Place: Chennai

Date: 28/05/2018

PRESS RELEASE

Revenue growth at 34%; PAT up 51%

5 Year CAGR – Revenue 32 % , EBDITA 51%, PBT 51% , PAT 54%

Results – Q4 FY 18 and FY 2018

Chennai, May 28, 2018: Caplin Point Laboratories Limited (BSE: CAPLL (524742), NSE: CAPLIPOINT) today reported its financial results for the Quarter (Q4 FY 18) and financial year ended March 31, 2018.

Key Financial & Performance Highlights – Consolidated (INR in lakhs)

Details	Q4 FY18	Q4 FY 17	Growth %	FY18	FY17	Growth
Gross Revenue	14630.94	12243.84	19%	55250.72	41160.38	34%
EBITDA	5161.75	4760.38	8%	20743.45	13437.29	54%
EBITDA %	35%	39%		38%	33%	
PBT	4542.82	4259.16	7%	18837.83	12094.70	56%
PBT %	31%	35%		34%	29%	

Key Financial & Performance Highlights – Standalone (INR in lakhs)

Details	Q4 FY18	Q4 FY 17	Growth %	FY18	FY17	Growth
Gross Revenue	11350.96	9814.51	16%	44988.72	35406.18	27%
EBITDA	3789.95	3508.23	8%	16510.20	10596.57	56%
EBITDA %	33%	36%		37%	30%	
PBT	3171.18	3001.71	6%	14605.30	9257.83	58%
PBT%	28%	31%		32%	26%	





Some of the key highlights of performance for the last year are captured below:

Financial (consolidated)

- ✓ Top line crossing INR 500cr mark - 34% growth over previous year
- ✓ Increase in Contribution Margin by INR 82cr - growth of 40% - higher than top line growth.
- ✓ Contribution % increased from 53 to 55 - 2 % on account of higher contribution from manufactured products (accounting for 60 % of growth in Revenue).
- ✓ Opex increase only by INR 20.3 cr (cash opex by INR 14.6 cr and depreciation by INR 5.7 cr). Opex as a % of Revenue decreased by 3 % (26 to 23) despite quantum increase of INR 20cr.
- ✓ PBT grew by INR 67 cr (121 to 188) - 56% growth over previous year. PBT as a % of Revenue jumped from 29 % to 34 %
- ✓ PAT registered a growth of INR 49 cr over previous year .
- ✓ EPS grew by 52% - from INR 12.65 to 19.26 - second successive year registering > 50 % YOY growth .
- ✓ Company invested close to INR 52 cr in Fixed Assets. One Third of Cash Profits invested in Fixed Assets.
- ✓ R & D spend at 23 % of PAT, with continued focus on new product development
- ✓ ROE at 50% (despite an increase of INR 120 cr in the Average Capital Employed over previous year).
- ✓ Debt-free Company (having Cash & Cash equivalents of INR 125cr, up from 110cr the previous year).
- ✓ Current asset management :
 - Less than 60 days consumption as inventory
 - Trade receivables - INR 126cr represent 86 days sales

Non-Financial

Emerging Markets

- ✓ Commercial entries into Chile, Paraguay, Panama and Costa Rica.
- ✓ Geographical Revenue Breakup : Latin America - 85%, Africa - 13%, US & other markets - 2%.
- ✓ New Liquid Injectable plant at CP 1 to be completed within the coming months, for Emerging markets. This facility is capable of manufacturing Injectables in Vials, Ampoules, Pre-Filled Syringes and Lyophilized Vials.
- ✓ Long Acting niche injectables under development, including emulsion and liposomal formulations.
- ✓ Recent launches of products in niche segments such as Pharma Softgels, Suppositories and Branded/OTC range contributes to growth.
- ✓ Plans underway to start a Clinical Research Organisation ('CRO') wing of Caplin, initially targeted at emerging markets, with mid-term plans to target



- ✓ Regulated markets such as US. One of the few companies in our size segment to go for own CRO operations. To become a commercial revenue generating operation over a period of time.
- ✓ **Awarded as "Emerging Company of 2018" by Economic Times Family Business Awards and "Best SME with Global Footprints" by ET Now, National Productivity Council and Arrucus Media.**

Regulated Markets

- ✓ Two ANDAs approved, one commercialized and one about to be commercialized in the coming months.
- ✓ 3 ANDAs filed and accepted for review, of which 2 are under Caplin's name.
- ✓ 7 more ANDAs targeted for filing under Caplin's name in FY 2018/19.
- ✓ Targeting 7 product filings in Brazil in the next 18 months.
- ✓ Plans underway to ramp up production capacity from CP-IV, regulated market plant, targeting 60 million units from Phase 1.
- ✓ Targeting a revenue mix of own ANDAs and Contract Manufacturing.
- ✓ R & D strength increased by another over 30% from last year to 180 scientists. R&D facility upgraded to 3x the size.

About Caplin Point Laboratories Limited:

Caplin Point Laboratories Limited is a niche pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has also entered regulated markets such as US through its Injectable & Ophthalmics facility that is approved by US FDA.

Caplin Point has been selected on Forbes Asia's "200 Best Under a Billion" list for three consecutive years (2014, 2015 & 2016), and was recently awarded "The Emerging Company of 2018" by Economic Times Family Business Awards.

Cautionary Statement:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

